FDA Lists More Than 1,500 AI-Enabled Medical Devices as Oncology Applications Expand
oncodaily - The U.S. Food and Drug Administration (FDA) has listed more than 1,500 artificial intelligence-enabled medical devices authorized for marketing in the United States, reflecting the growing integration of AI across […]
AI Summary: The FDA catalogued more than 1,500 AI‑enabled medical devices, spurring criticism that most were cleared without direct evidence they improve patient outcomes. Regulators and clinicians face mounting calls for post‑market studies and transparency, balancing enthusiasm for AI innovation against the sober question: do these devices actually help patients?
NCCS Develops AI Tool to Predict Liver Cancer Recurrence After Surgery
oncodaily - National Cancer Centre Singapore (NCCS) shared on LinkedIn: “Can we now predict who’s at greatest risk for liver cancer recurrence? Congratulations to NCCS’ Professor Pierce Chow, Associate Professor Wai Leong Tam, Mr. Karthik Sekar, […]
AI Summary: A newly developed AI model predicts risk of liver cancer recurrence following surgical resection, integrating imaging and clinical variables to stratify patients more accurately. Early validation suggests the tool could personalize surveillance intensity and adjuvant therapy decisions, reducing unnecessary exams for low‑risk patients while focusing resources where recurrence risk is highest.
There are new blood tests for Alzheimer's. Should I have one?
medicalxpress - Australians have seen a flurry of headlines announcing the arrival of blood tests for Alzheimer's disease.
AI Summary: New blood tests detecting Alzheimer’s biomarkers are reaching clinical availability, promising earlier and less invasive diagnosis. Clinicians and consumers now face decisions about who should be tested, how to interpret results, and what interventions — if any — follow a positive biomarker. The tests shift diagnostic practice while raising ethical and counseling challenges.
Cardinal Health to buy Strive Medical, AdaptHealth's diabetes health business for $360M
fiercehealthcare - The pharmaceuticals and specialty products distributor plans to buy AdaptHealth's diabetes health business unit and medical supply provider Strive Medical in separate deals worth $360 million.
AI Summary: Cardinal Health agreed to buy AdaptHealth/Strive Medical’s diabetes health business for roughly $360 million and pursue additional acquisitions to expand its at‑home care portfolio. The moves aim to accelerate home‑based services and chronic disease support, reflecting a broader industry push to shift care out of hospitals and into patients' living rooms.
Breathalyzer can 'sniff out' when your body starts burning fat
medicalxpress - Researchers have developed a breath detector with a chemical sensor that sniffs out when your body is burning fat through a single exhale. Reporting in Device, the handheld, smartphone-assisted device measures acetone—a molecule that is released into the …
AI Summary: Engineers developed a breath-based detector that pinpoints when the body shifts to fat oxidation, and shrank it down to a phone-compatible breathalyser. The device measures volatile markers in exhaled breath to indicate metabolic state, enabling noninvasive, real‑time monitoring of fat burning for weight-loss or metabolic research — because your phone now judges your dinner choices.
Samsung launches beta version of AI-powered health assistant across US
fiercehealthcare - The tool, dubbed Samsung Health Assistant, allows users to ask questions and receive personalized guidance and recommendations in the Samsung Health app.
AI Summary: Samsung has launched a beta version of its AI‑powered health assistant across the United States, offering consumers an on‑device tool to track and manage health tasks. The rollout tests functionality and user engagement while reminding everyone that “beta” often means “expect surprises,” particularly when medicine and machine learning meet.
2nd scan uncovers missed prostate cancer, changes care for nearly half of patients: 4 notes
Ella Jeffries / beckershospitalreview - A second scan using prostate-specific membrane antigen positron emission tomography changed treatment plans for nearly half of patients with recurrent prostate cancer whose initial scan was negative, according to research published in the July issue of Th…
AI Summary: Follow-up prostate-specific membrane antigen (PSMA) PET imaging uncovered disease missed on initial scans and altered management in nearly half of patients. Repeat imaging revealed occult or more extensive disease, prompting switches from surveillance to definitive or systemic therapies and adjustments to radiation plans. The data argue for selective reimaging when staging is uncertain.
Former Mayo Clinic Leader Sues System Over Alleged AI Cover-Up: 6 Things to Know
Katie Adams / medcitynews - A former Mayo Clinic research director claims she was silenced, demoted and ultimately fired for sounding the alarm on AI safety and patient privacy lapses at the health system. Traci Tamiko Eto is now suing Mayo for retaliation.The post Former Mayo Clini…
AI Summary: A former Mayo Clinic research director has filed suit alleging retaliation after raising concerns about the health system’s use and oversight of clinical AI. The complaint accuses leadership of suppressing warnings, sidelining the whistleblower and covering up problematic practices — seeking damages and reforms while triggering closer scrutiny of institutional AI governance.
- Clinical AI expansion, partnerships and industry pitfalls (5)
- Mayo whistleblower lawsuit alleges AI cover-up (3)
Clinical AI expansion, partnerships and industry pitfalls
Mayo whistleblower lawsuit alleges AI cover-up
Two tests GPs can soon offer to help spot endometriosis
bbc - Experts hope they will be a game-changer and cut the nine-year or longer diagnosis waits patients can currently face.
AI Summary: Emerging research on hormonal signatures and blood biomarkers has led to development of tests GPs may soon use to spot endometriosis earlier. Patient accounts underline the life‑changing potential of timely diagnosis. The work promises less guesswork, fewer invasive procedures, and fewer years lost to unexplained pain—so yes, medicine might actually make life convenient for once.
- GP tests and NHS rollout to shorten diagnosis (3)
- Hormone and symptom research reveals diagnostic signatures (3)
- Work, wellbeing and cost pressures on patients (3)
GP tests and NHS rollout to shorten diagnosis
Hormone and symptom research reveals diagnostic signatures
Work, wellbeing and cost pressures on patients
AI system detects sudden cardiac death risk, identifying thousands more patients annually
medicalxpress - Each year in the U.S., more than 300,000 people die from sudden cardiac arrest, a condition in which the heart's electrical system malfunctions without warning. The medical emergency can kill both high-risk older adults and young athletes with no history …
AI Summary: New AI tools claim to identify far more patients at risk of sudden cardiac death than traditional metrics, detecting subtle patterns invisible to clinicians. Early studies suggest strong sensitivity gains, but experts caution that screening scale‑up, false positives and prospective validation will determine whether the tech saves lives or simply creates more testing.
Generative AI-enabled clinical decision support system in primary care: a pragmatic, cluster-randomized trial
Ambrose Agweyu / nature - Nature Medicine, Published online: 26 June 2026; doi:10.1038/s41591-026-04503-6A pragmatic cluster-randomized trial found that ChatGPT-4o-assisted decision support in Kenyan primary care facilities did not significantly reduce 14-day treatment failure ove…
AI Summary: A pragmatic, cluster‑randomized trial showed that a generative AI clinical decision support tool improved clinician decision‑making in real‑world primary care settings. The results suggest practical benefits beyond pilot hype, though implementation, safety and privacy challenges remain on the checklist before widescale roll‑out.
Hathal Haddad: 28 Days Until Brachytherapy Awareness Day 2026
oncodaily - Hathal Haddad, Head of Interventional Radiotherapy Unit at the Department of Radiation Oncology at University Hospital Tübingen, shared a post on LinkedIn: “28 Days Until Brachytherapy Awareness Day 2026 The Original Adaptive […]
AI Summary: Radiation oncologists and advocates are publicly gearing up for Brachytherapy Awareness Day, using countdowns and outreach to raise awareness of image‑guided and salvage brachytherapy techniques. The push emphasizes education, patient access and the specialty’s role in targeted cancer treatment — all packaged with the predictable mix of pride and promotional zeal.
- Countdown and technique spotlights ahead of Brachytherapy Awareness Day (4)
- Guidelines, re-irradiation debates and professional meeting updates (4)
Countdown and technique spotlights ahead of Brachytherapy Awareness Day
Guidelines, re-irradiation debates and professional meeting updates
IRhythm discloses data stolen from third-party applications in cyberattack
Ricky Zipp / healthcaredive - The cardiac monitoring company said that a threat actor has demanded payment in exchange for not publicly releasing the stolen data.
AI Summary: IRhythm announced a cybersecurity incident involving stolen data from third‑party applications and is investigating the breach. Limited patient information may have been exposed, prompting notifications and security reviews. The episode starkly illustrates how digital‑health vendors remain attractive targets and how compromises of ancillary systems can ripple into real patient risk.
CMS creates Office of Health Technology and Products
Naomi Diaz / beckershospitalreview - The Centers for Medicare & Medicaid Services has established a new Office of Health Technology and Products to oversee healthcare technology modernization, digital products and platform transformation across the agency’s programs. The organizational chang…
AI Summary: CMS has created a dedicated Office of Health Technology and Products to centralize oversight of digital health tools, including AI and emerging medical technologies. The new office will coordinate evaluation, guidance and implementation policies across CMS programs to speed safe adoption, improve interoperability and provide clearer regulatory expectations for health systems and vendors.
Implanted radiation device cuts brain tumor recurrence: 5 study notes
Ella Jeffries / beckershospitalreview - An implanted radiation device has improved tumor control and overall survival compared with standard radiation therapy in patients with newly diagnosed operable brain metastases, according to phase 3 clinical trial data presented May 30 at the American So…
AI Summary: Clinical trial data show an implanted "tile" radiation device placed at resection sites lowers local recurrence risk for patients with brain metastases. The approach provides a targeted, intraoperative boost that shortens treatment timelines — and gives surgeons one more tool to argue they cured something before the tumor disagreed.
WellSpan Health, Philips launch 7-year AI, imaging partnership
Naomi Diaz / beckershospitalreview - York, Pa.-based WellSpan Health and Royal Philips have entered a seven-year strategic alliance covering advanced imaging technology, AI-enabled care and a joint research and co-development agreement across WellSpan’s 12 hospitals, diagnostic imaging cente…
AI Summary: WellSpan Health and Philips announced a seven-year collaboration to co-develop and deploy AI-enabled imaging solutions across the health system. The agreement aims to accelerate diagnostic imaging innovation, integrate AI into clinical workflows and support research — effectively a bet that smarter machines can shave time off scans and maybe improve patient outcomes.
New Tool That Tracks How the Brain Removes Waste Could Offer Clues About Alzheimer’s
discovermagazine - Learn why understanding how the brain clears its waste could help researchers combat neurodegenerative diseases and age-related cognitive decline.
AI Summary: Researchers unveiled an imaging tool that tracks how the brain removes metabolic waste, mapping preferred drainage routes and pinpointing breakdowns associated with Alzheimer’s pathology. The technique could flag early clearance failure years before symptoms, offering potential biomarkers and therapeutic targets—because sometimes the answer to dementia is less about neurons and more about the plumbing.
Smart ring maker Oura files confidentially for IPO as consumer demand propels revenue growth
fiercehealthcare - Oura, the smart ring maker, filed confidentially for an initial public offering after it reached an $11 billion valuation last year.
AI Summary: Ōura has quietly filed confidential paperwork to go public, leveraging surging consumer demand for its smart rings and an aggressive pivot into healthcare data and services. The company is pitching its wearable as a clinical-grade monitoring platform to insurers and providers, aiming to monetize sleep, activity and biometrics while navigating privacy and regulatory scrutiny.
Depressed mice successfully treated with smart contact lenses that zap their brains: New study
medicalxpress - Scientists in South Korea have developed experimental contact lenses designed to send electrical signals through the retina and into brain regions linked to mood. In mice, the technology appeared to improve depression-like behavior.
AI Summary: Preclinical studies report smart contact lenses that deliver tiny electrical signals can reduce depressive-like behaviors in mice, matching effects seen with standard antidepressants. Researchers caution the work is early — promising biologically, but still a long way from fashionable therapeutic eyewear for humans — and will require safety, dosing and translational studies before any clinic-ready hype.
Omid Veiseh: First-in-Human Clinical Trial of IL-2 Cytokine Factories in Refractory Ovarian Cancer
oncodaily - Omid Veiseh, Professor and CPRIT Scholar in Cancer Research at Rice University and Co-Founder and Managing Partner of RBL LLC, shared a post on LinkedIn: “Excited to publish the results […]
AI Summary: A first‑in‑human trial of implantable IL‑2 “cytokine factories” in refractory ovarian cancer reported encouraging early safety and biological activity, offering a localized immune‑stimulation strategy that may boost tumor responses while avoiding systemic toxicity. Investigators described the device‑based platform as a potential option for patients with limited alternatives, pending larger efficacy studies.